{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T16:04:04Z","timestamp":1792857844578,"version":"4.5.0"},"reference-count":34,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2025,5,1]]},"abstract":"\n Importance<\/jats:title>\n Optimal adjuvant treatment for patients with intermediate-risk cervical cancer remains controversial, and the benefit of adding chemotherapy to radiotherapy in this population is uncertain.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate whether adjuvant chemoradiotherapy is associated with improved overall survival compared with radiotherapy alone in patients with intermediate-risk cervical cancer. Secondary objectives included identifying clinical factors associated with the use of chemoradiotherapy.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n A cohort study was conducted at Commission on Cancer\u2013accredited centers across the US using prospectively collected data from the National Cancer Database that focused on patients with a diagnosis of 2018 International Federation of Gynecology and Obstetrics stage IB cervical carcinoma (squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma) of intermediate risk who were undergoing adjuvant radiotherapy treatment after radical hysterectomy from January 2010 through December 2020. Missing variables were multiple imputed, and propensity score matching (1:1) was performed to balance baseline characteristics. A Kaplan-Meier analysis and proportional hazard models were used to compare the hazard of death between the groups.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Adjuvant radiotherapy alone vs concurrent chemoradiotherapy.<\/jats:p>\n <\/jats:sec>\n \n Main Outcome and Measure<\/jats:title>\n The primary outcome was time to death or last follow-up.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 1116 patients (mean [SD] age, 47 [12] years) were identified, of whom 486 (43.5%) received concurrent chemoradiotherapy. Chemotherapy was administered more frequently among those with adenocarcinoma or adenosquamous histology compared with squamous cell carcinoma (risk ratio [RR], 1.26; 95% CI, 1.10-1.44) and those with tumors larger than 4 cm (compared with tumors measuring 2-4 cm; RR, 1.31; 95% CI, 1.14-1.51). Propensity score matching yielded a cohort of 868 patients with balanced covariates. Patients who received chemoradiotherapy had similar overall survival (5- year survival, 87%) as those who received radiotherapy alone (5-year survival, 87%; hazard ratio, 0.85; 95% CI, 0.59-1.23;\n P<\/jats:italic>\n \u2009=\u2009.38). There were no significant differences in survival associated with chemotherapy receipt among subgroups defined by tumor size, histology, presence of lymphovascular space invasion, surgical approach, or receipt of adjuvant brachytherapy.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n The results of this cohort study suggest that adding chemotherapy to radiotherapy was not associated with improved overall survival for patients with intermediate-risk cervical cancer.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaoncol.2025.0146","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T11:03:16Z","timestamp":1741863796000},"page":"511","source":"Crossref","is-referenced-by-count":17,"title":["Adjuvant Chemoradiotherapy vs Radiotherapy Alone for Patients With Intermediate-Risk Cervical Cancer"],"prefix":"10.1001","volume":"11","author":[{"given":"N\u00faria","family":"Agust\u00ed","sequence":"first","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Viveros-Carre\u00f1o","sequence":"additional","affiliation":[{"name":"Unidad Ginecolog\u00eda Oncol\u00f3gica, Grupo de Investigaci\u00f3n GIGA, Centro de Tratamiento e Investigaci\u00f3n sobre C\u00e1ncer Luis Carlos Sarmiento Angulo\u2013CTIC, Bogot\u00e1, Colombia"},{"name":"Cl\u00ednica Universitaria Colombia, Bogot\u00e1, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Fang","family":"Wu","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roni Nitecki","family":"Wilke","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa","family":"Kanbergs","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla","family":"Barajas","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail S.","family":"Zamorano","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Pareja","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology, Cl\u00ednica Astorga, Medell\u00edn, Colombia"},{"name":"Department of Gynecologic Oncology, Instituto Nacional de Cancerolog\u00eda, Bogot\u00e1, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Melamed","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Alejandro","family":"Rauh-Hain","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"coi250004r1","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1136\/ijgc-2023-004429","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with cervical cancer\u2014update 2023.","volume":"33","author":"Cibula","year":"2023","journal-title":"Int J Gynecol Cancer"},{"issue":"12","key":"coi250004r2","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.6004\/jnccn.2023.0062","article-title":"NCCN guidelines insights: cervical cancer, version 1.2024.","volume":"21","author":"Abu-Rustum","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"coi250004r3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1006\/gyno.1999.5387","article-title":"A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group study.","volume":"73","author":"Sedlis","year":"1999","journal-title":"Gynecol Oncol"},{"issue":"3","key":"coi250004r4","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002225.pub2","article-title":"Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix.","volume":"2005","author":"Green","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"coi250004r5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.tjog.2021.11.006","article-title":"Comparison of adjuvant chemoradiotherapy versus radiotherapy in early-stage cervical cancer patients with intermediate-risk factors: a systematic review and meta-analysis.","volume":"61","author":"Guo","year":"2022","journal-title":"Taiwan J Obstet Gynecol"},{"issue":"3","key":"coi250004r6","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.ygyno.2009.09.002","article-title":"Postoperative concurrent nedaplatin-based chemoradiotherapy improves survival in early-stage cervical cancer patients with adverse risk factors.","volume":"115","author":"Mabuchi","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"3","key":"coi250004r7","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.ijrobp.2009.11.019","article-title":"Is adjuvant chemoradiotherapy overtreatment in cervical cancer patients with intermediate risk factors?","volume":"79","author":"Ryu","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"coi250004r8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ygyno.2011.09.033","article-title":"20 year experience of postoperative radiotherapy in IB-IIA cervical cancer patients with intermediate risk factors: impact of treatment period and concurrent chemotherapy.","volume":"124","author":"Song","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"2","key":"coi250004r9","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ejso.2008.04.004","article-title":"Comparison of chemoradiation with radiation as postoperative adjuvant therapy in cervical cancer patients with intermediate-risk factors.","volume":"35","author":"Kim","year":"2009","journal-title":"Eur J Surg Oncol"},{"issue":"3","key":"coi250004r10","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s00404-021-05989-w","article-title":"Is there a benefit for adjuvant radio(chemo)therapy in early cervical cancer? Results from a population-based study.","volume":"304","author":"Scharl","year":"2021","journal-title":"Arch Gynecol Obstet"},{"issue":"1","key":"coi250004r11","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1186\/s12885-015-1355-1","article-title":"Randomized phase III trial of radiotherapy or chemoradiotherapy with topotecan and cisplatin in intermediate-risk cervical cancer patients after radical hysterectomy.","volume":"15","author":"Sun","year":"2015","journal-title":"BMC Cancer"},{"key":"coi250004r12","doi-asserted-by":"publisher","first-page":"7331","DOI":"10.2147\/OTT.S107146","article-title":"Postoperative adjuvant chemotherapy combined with intracavitary brachytherapy in early-stage cervical cancer patients with intermediate risk factors.","volume":"9","author":"Yu","year":"2016","journal-title":"Onco Targets Ther"},{"issue":"3","key":"coi250004r13","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.ygyno.2016.10.022","article-title":"Can chemotherapy boost the survival benefit of adjuvant radiotherapy in early stage cervical cancer with intermediate risk factors? A population based study.","volume":"143","author":"Mahmoud","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"8","key":"coi250004r14","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1136\/ijgc-2024-005570","article-title":"Adjuvant external beam radiotherapy combined with brachytherapy for intermediate-risk cervical cancer.","volume":"34","author":"Agusti","year":"2024","journal-title":"Int J Gynecol Cancer"},{"issue":"12","key":"coi250004r15","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1001\/jamaoncol.2016.6905","article-title":"Using the national cancer database for outcomes research a review.","volume":"3","author":"Boffa","year":"2017","journal-title":"JAMA Oncol"},{"issue":"6","key":"coi250004r16","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1136\/ijgc-2021-002489","article-title":"Role of adjuvant radiation therapy after radical hysterectomy in patients with stage IB cervical carcinoma and intermediate risk factors.","volume":"31","author":"Nasioudis","year":"2021","journal-title":"Int J Gynecol Cancer"},{"key":"coi250004r17","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2022-003918","article-title":"CERVANTES: an international randomized trial of radical surgery followed by adjuvant (chemo) radiation versus no further treatment in patients with early-stage, intermediate-risk cervical cancer (CEEGOG-CX-05; ENGOT-CX16).","volume":"\u2022\u2022\u2022","author":"Cibula","year":"2022","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"coi250004r18","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/sim.4067","article-title":"Multiple imputation using chained equations: issues and guidance for practice.","volume":"30","author":"White","year":"2011","journal-title":"Stat Med"},{"issue":"1","key":"coi250004r19","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12874-015-0022-1","article-title":"The rise of multiple imputation: a review of the reporting and implementation of the method in medical research.","volume":"15","author":"Hayati Rezvan","year":"2015","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"coi250004r20","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2020.31.e80","article-title":"Does adenocarcinoma have a worse prognosis than squamous cell carcinoma in patients with cervical cancer? a real-world study with a propensity score matching analysis.","volume":"31","author":"Pan","year":"2020","journal-title":"J Gynecol Oncol"},{"issue":"10","key":"coi250004r21","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1093\/annonc\/mdg412","article-title":"Prognostic value of lymphovascular space invasion determined with hematoxylin-eosin staining in early stage cervical carcinoma: results of a multivariate analysis.","volume":"14","author":"Morice","year":"2003","journal-title":"Ann Oncol"},{"issue":"20","key":"coi250004r22","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1056\/NEJMoa1806395","article-title":"Minimally invasive versus abdominal radical hysterectomy for cervical cancer.","volume":"379","author":"Ramirez","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"coi250004r23","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-Value.","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"issue":"1","key":"coi250004r24","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ijrobp.2005.10.019","article-title":"A phase III randomized trial of postoperative pelvic irradiation in stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study.","volume":"65","author":"Rotman","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"coi250004r25","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.ygyno.2018.10.018","article-title":"Surgical treatment of \u201cintermediate risk\u201d lymph node negative cervical cancer patients without adjuvant radiotherapy\u2014a retrospective cohort study and review of the literature.","volume":"151","author":"Cibula","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"10","key":"coi250004r26","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1136\/ijgc-2022-003735","article-title":"Adjuvant treatment after radical surgery for cervical cancer with intermediate risk factors: is it time for an update?","volume":"32","author":"Rodriguez","year":"2022","journal-title":"Int J Gynecol Cancer"},{"issue":"8","key":"coi250004r27","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1200\/JCO.2000.18.8.1606","article-title":"Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix.","volume":"18","author":"Peters","year":"2000","journal-title":"J Clin Oncol"},{"issue":"3","key":"coi250004r28","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2020.31.e35","article-title":"Chemoradiotherapy is not superior to radiotherapy alone after radical surgery for cervical cancer patients with intermediate-risk factor.","volume":"31","author":"Kim","year":"2020","journal-title":"J Gynecol Oncol"},{"issue":"4","key":"coi250004r29","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/aje\/kws412","article-title":"The table 2 fallacy: presenting and interpreting confounder and modifier coefficients.","volume":"177","author":"Westreich","year":"2013","journal-title":"Am J Epidemiol"},{"issue":"3","key":"coi250004r30","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1001\/jamaoncol.2020.7168","article-title":"Effectiveness of sequential chemoradiation vs concurrent chemoradiation or radiation alone in adjuvant treatment after hysterectomy for cervical cancer: the STARS phase 3 randomized clinical trial.","volume":"7","author":"Huang","year":"2021","journal-title":"JAMA Oncol"},{"issue":"9","key":"coi250004r31","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1136\/ijgc-2024-005597","article-title":"Assessment of postoperative therapy de-escalation for early-stage, intermediate-risk cervical cancer.","volume":"34","author":"Matsuo","year":"2024","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"coi250004r32","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.ygyno.2010.11.022","article-title":"A comparison of pure adenocarcinoma and squamous cell carcinoma of the cervix after radical hysterectomy in stage IB-IIA.","volume":"120","author":"Lee","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"8","key":"coi250004r33","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1136\/ijgc-2020-001436","article-title":"Measurement of tumor size in early cervical cancer: an ever-evolving paradigm.","volume":"30","author":"Salvo","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"coi250004r34","unstructured":"NRG Oncology. GOG-0236. Accessed January 5, 2025. https:\/\/www.nrgoncology.org\/Clinical-Trials\/Protocol\/gog-0263?filter=gog-0263"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2830964\/jamaoncology_agust_2025_oi_250004_1747255290.70317.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T11:02:53Z","timestamp":1747306973000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2830964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2025.0146","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,1]]}}}